Tumor sample context
Tumor type, collection site, sample condition, expected timing and available ethics documentation.
Mesenchymal tumor PDO
Case-specific model development, phenotype profiling and candidate-response studies for GIST, osteosarcoma and related tumors.
Pathology-definedMutation-definedProtein markers
Model source
Patient tumor tissue with pathology-guided, case-specific design
Culture / format
Custom 3D culture
Supporting evidence
TRiCBIO culture and project cases
Model characterization
How the model is established and characterized
Source-tissue and organoid imaging plus lineage/identity markers characterize the model; functional readouts are selected for the candidate mechanism and study objective.
View imageCustom GIST models: bright-field culture morphology, source-tissue H&E and culture H&E compare spindle and mixed spindle/epithelioid patterns for case-specific pathology reference and model QC.
Study data
View imageCustom osteosarcoma models: H&E and marker panels across source tissue, PDO and primary tissue compare identity, proliferation and lineage-associated phenotypes for downstream assay selection.
Study dataStudy planning
From study objective to model and assay plan
Tumor type, sample condition, candidate and intended comparison guide the culture format, controls and assays.
Candidate and study objective
Modality, dosing plan, controls and the response or comparison the study should address.
Assays and deliverables
Planned histology, flow, molecular or functional assays, together with preferred data and report formats.
Study design
Let pathology and molecular context define rare-tumor modeling
GIST, osteosarcoma and other mesenchymal tumors have distinct pathology and molecular profiles, calling for tailored model establishment, identity QC, treatment-response and mechanism studies.
Pathology and sample assessment
Assess diagnosis, sampling site, tissue state and molecular records.
Culture performance and expansion
Assess growth patterns and reproducible morphology before expanding the model.
Build case-specific QC
Use source H&E, organoid bright-field, organoid H&E and pathology-relevant markers.
Move into treatment and mechanism studies
Once model identity and culture performance are confirmed, progress into treatment response, functional phenotype or mechanism studies.
Research applications
Recommended applications
- Mesenchymal or rare tumor model establishment
- Tissue morphology and molecular features
- Candidate-response studies
Assays & QC
Tumor identity, efficacy and immune readouts
Key markers
Pathology-definedMutation-definedProtein markers
Available assays
- H&E
- Molecular testing
- Protein expression
- Viability
QC approach
Case-specific QC is based on pathology, morphology, mutation or protein markers.
Study & delivery
Model characterization, treatment data and reporting
Pathology-guided model establishment, characterization and candidate studies, with corresponding data and reporting.
Related solutions
Related study options
PROJECT DISCUSSION
Discuss a rare-tumor study
Tumor type, sample status, candidate profile and comparison endpoints determine the culture format, controls, assay panel and deliverables for the mesenchymal tumor PDO.